High intake of the artificial sweetener sucralose may reduce the efficacy of ICIs in patients with cancer, data suggest.

Research links environmental exposures to CKD development and progression. Here’s what clinicians and patients need to know.

Prevalence of glycemic control and use of diabetes technology lowest in Hispanic, non-Hispanic Black, Medicaid-insured.

Research teams investigated the association between hemoglobin levels and cognitive impairment in patients with chronic kidney disease (CKD) or end-stage (ESKD).

The FDA has approved an expanded indication of the IV formulation of Avtozma to include the treatment of CRS in patients 2 years of age and older.

Findings seen across body mass index groups. (HealthDay News) — Metformin use is associated with lower risks for dementia and all-cause mortality across body mass index (BMI) groups in patients ...

(HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by the ...

The Food and Drug Administration (FDA) has approved the first generic version of Venofer ® (iron sucrose) Injection.

Pembrolizumab plus lenvatinib is currently a standard of care for clear-cell renal cell carcinoma (RCC), so investigators assessed the combination for non-clear-cell RCC.

DASH, DII are significantly associated with CKD risk, while only DII is associated with CKD severity progression.